Applied Therapeutics, Inc. (APLT)

Market Cap	61.67M
Revenue (ttm)	-212,000
Net Income (ttm)	-187.31M
Shares Out	116.36M
EPS (ttm)	-1.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,288,230
Open	0.561
Previous Close	0.565
Day's Range	0.530 - 0.592
52-Week Range	0.530 - 10.620
Beta	1.88
Analysts	Buy
Price Target	6.10 (+1,050.94%)
Earnings Date	Mar 5, 2025

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of ph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2019
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: APLT
• Website: https://www.appliedtherapeutics.com

Analyst Forecast

According to 7 analysts, the average rating for APLT stock is "Buy." The 12-month stock price forecast is $6.1, which is an increase of 1,050.94% from the latest price.

Price Target

$6.1

(1,050.94% upside)

Analyst Consensus: Buy